Education
About Us
Working with TipRanks
Follow Us
Can-Fite BioPharma (CANF)
:CANF
CANF Stock Chart & Stats
$0.47
-$0.06(-3.61%)
At close: 4:00 PM EST
$0.47
-$0.06(-3.61%)
Day’s Range― - ―
52-Week Range$0.47 - $3.02
Previous CloseN/A
Volume35.97K
Average Volume (3M)258.05K
Market Cap
$15.73M
Enterprise Value$5.58M
Total Cash (Recent Filing)$6.46M
Total Debt (Recent Filing)$90.00K
Price to Earnings (P/E)―
Beta1.01
Next Earnings
Nov 21, 2025EPS Estimate
-0.14Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)-0.14
Shares Outstanding17,072,916
10 Day Avg. Volume432,468
30 Day Avg. Volume258,053
Financial Highlights & Ratios
PEG Ratio0.04
Price to Book (P/B)2.18
Price to Sales (P/S)17.54
P/FCF Ratio-1.55
Enterprise Value/Market Cap0.35
Enterprise Value/Revenue9.96
Enterprise Value/Gross Profit9.96
Enterprise Value/Ebitda-0.63
Forecast
1Y Price TargetN/A
Price Target UpsideN/A
Rating ConsensusModerate Sell
Number of Analyst Covering0
Can-Fite BioPharma News
CANF FAQ
What was Can-Fite BioPharma’s price range in the past 12 months?
Can-Fite BioPharma lowest stock price was $0.47 and its highest was $3.02 in the past 12 months.
What is Can-Fite BioPharma’s market cap?
Can-Fite BioPharma’s market cap is $15.73M.
When is Can-Fite BioPharma’s upcoming earnings report date?
Can-Fite BioPharma’s upcoming earnings report date is Nov 21, 2025 which is in 24 days.
How were Can-Fite BioPharma’s earnings last quarter?
Can-Fite BioPharma released its earnings results on Aug 28, 2025. The company reported -$0.144 earnings per share for the quarter, missing the consensus estimate of -$0.11 by -$0.034.
Is Can-Fite BioPharma overvalued?
According to Wall Street analysts Can-Fite BioPharma’s price is currently Overvalued.
Does Can-Fite BioPharma pay dividends?
Can-Fite BioPharma does not currently pay dividends.
What is Can-Fite BioPharma’s EPS estimate?
Can-Fite BioPharma’s EPS estimate is -0.14.
How many shares outstanding does Can-Fite BioPharma have?
Can-Fite BioPharma has 17,072,916 shares outstanding.
What happened to Can-Fite BioPharma’s price movement after its last earnings report?
Can-Fite BioPharma reported an EPS of -$0.144 in its last earnings report, missing expectations of -$0.11. Following the earnings report the stock price went same 0%.
Which hedge fund is a major shareholder of Can-Fite BioPharma?
Currently, no hedge funds are holding shares in CANF
Company Description
Can-Fite BioPharma
Can-Fite BioPharma Ltd. is a clinical-stage biopharmaceutical company focused on developing innovative therapies for the treatment of cancer, inflammatory diseases, and liver diseases. The company is headquartered in Israel and specializes in the discovery and development of proprietary small molecule drugs, with its core products including Namodenoson, a novel drug candidate for liver cancer and other indications, as well as additional pipeline candidates targeting various conditions. Can-Fite's therapeutic approach is based on its understanding of the role of the A3 adenosine receptor in disease processes, positioning it in the biotechnology sector with a focus on unmet medical needs.
Technical Analysis
Ownership Overview
―
Insiders
―
Mutual Funds
4.67% Other Institutional Investors
95.33% Public Companies and
Individual Investors
Options Prices
Currently, No data available
---